Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
RESEARCH TOOLSreports
Holding OPT?
Track your performance easily
OPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.79 - $5.45
Previous Close$3.13
Volume4.26K
Average Volume (3M)29.43K
Market Cap
$501.38M
Enterprise Value$329.00M
Total Cash (Recent Filing)$172.47M
Total Debt (Recent Filing)$93.03K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Feb 26, 2025EPS Estimate
-$1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding153,886,827
10 Day Avg. Volume46,275
30 Day Avg. Volume29,426
Standard Deviation0.19
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-6.69
Price to Sales (P/S)4024.12
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.64K
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.75Price Target Upside271.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Opthea Limited Sponsored ADR News
PremiumCompany Announcements
Opthea Limited Targets AMD Market with Sozinibercept
PremiumCompany Announcements
Opthea Limited Strengthens Leadership and Advances AMD Treatment
PremiumCompany Announcements
Opthea Advances Retinal Disease Treatments
PremiumCompany Announcements
Opthea Advances nAMD Treatment with Sozinibercept
PremiumCompany Announcements
Opthea Advances Toward Sozinibercept CommercializationBulls Say, Bears Say
Bulls Say
Clinical TrialsTopline data from sozinibercept's Phase 3 wet AMD trials, COAST and ShORe, remain on track.
Financial StabilityOpthea has ~US$207mn in pro forma cash and appears well-funded through 2025 pivotal readouts.
Product EfficacySozinibercept combination therapy achieved its positive Phase 2b primary efficacy endpoint with statistically superior visual acuity gains at 24-weeks versus Lucentis (ranibizumab) alone.
Bears Say
Clinical TrialsDelays or unfavorable outcomes from the ongoing clinical trials could affect the company’s valuation.
Regulatory ApprovalsMaterial delays or failure to obtain regulatory approvals for sozinibercept in wAMD could severely affect the viability of Opthea business as a going concern.
Stock Price TargetThe price target is reduced from $14 to $12 per share.
---
Ownership Overview
―
Insiders
0.44% Mutual Funds
3.33% Other Institutional Investors
96.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
OPT FAQ
What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $1.79 and its highest was $5.45 in the past 12 months.
What is Opthea Limited Sponsored ADR’s market cap?
Currently, no data Available
When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
Opthea Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Opthea Limited Sponsored ADR’s earnings last quarter?
Opthea Limited Sponsored ADR released its earnings results on Aug 30, 2024. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.72.
Is Opthea Limited Sponsored ADR overvalued?
According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Undervalued.
Does Opthea Limited Sponsored ADR pay dividends?
Opthea Limited Sponsored ADR does not currently pay dividends.
What is Opthea Limited Sponsored ADR’s EPS estimate?
Opthea Limited Sponsored ADR’s EPS estimate is -$1.11.
How many shares outstanding does Opthea Limited Sponsored ADR have?
Opthea Limited Sponsored ADR has 153,886,830 shares outstanding.
What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
Opthea Limited Sponsored ADR reported an EPS of -$1.52 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went up 1.65%.
Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
Among the largest hedge funds holding Opthea Limited Sponsored ADR’s share is Baker Bros Advisors LP. It holds Opthea Limited Sponsored ADR’s shares valued at 9M.
---
Opthea Limited Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (271.85% Upside)
$11.75 (271.85% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
91.39%
Trailing 12-Months
Company Description
Opthea Limited Sponsored ADR
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
---
OPT Stock 12 Month Forecast
Average Price Target
$11.75
▲(271.85% Upside)
Technical Analysis
Best Analysts Covering OPT
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-19.80%
reiterated a buy rating 3 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -19.80% per trade.
---